Skip to content
Dosage GuideResearch Reference

Survodutide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Survodutide. All information is for educational purposes only.

Quick Answer

In Phase 2 clinical trials, survodutide has been administered at doses ranging from 0.6 mg to 4.8 mg weekly via subcutaneous injection. Dosing is typically escalated gradually to minimize gastrointestinal side effects. Phase 3 trials are exploring similar dose ranges. No specific off-label dose recommendations exist.

→ Survodutide Benefits→ Survodutide Side Effects→ Full Survodutide Profile
Table of Contents

Standard Dosage Range

Research dosing range: 0.6–4.8 mg per week (subcutaneous injection)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Weight Loss (Obesity)

0.6–4.8 mgOnce weekly
Duration

Ongoing (long-term maintenance)

Dose escalation is essential to mitigate nausea. Start at 0.6 mg and increase gradually (e.g., by 0.6 mg increments every 4 weeks) to the target dose of 4.8 mg or maximum tolerated dose. Administer subcutaneously, rotating injection sites.

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

2.4–4.8 mgOnce weekly
Duration

48 weeks+

Higher doses within the range may be more effective for liver fat reduction. Continue monitoring liver enzymes and biopsy if indicated. Dose escalation as tolerated.

Type 2 Diabetes (adjunct therapy)

1.2 - 4.8 mgOnce weekly
Duration

Ongoing (long-term glycemic control)

Use in conjunction with existing diabetes medications (e.g., metformin, SGLT2 inhibitors). Monitor blood glucose levels closely, especially during dose titration, to avoid hypoglycemia. Adjust concurrent diabetes medications as needed.

Timing & Frequency

Administer survodutide once weekly at any time of day, with or without meals. Consistency in timing may help minimize side effects. Rotate injection sites to prevent skin reactions.

Cycle Guidance

Clinical trials have used continuous administration for up to 48 weeks. Given the long half-life, cycling is likely unnecessary from a receptor desensitization perspective. However, long-term safety data is still emerging, so continuous use should be guided by a healthcare professional.

Reconstitution Reference

Quick reference for reconstituting Survodutide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizePre-filled pen or single-dose vial
BAC Water VolumeN/A - Supplied as a ready-to-inject solution
Concentration & DrawVaries depending on product. Check the label for concentration (e.g., mg/mL).
StorageRefrigerate at 2–8°C until use. Protect from light. Do not freeze.
StabilityRefer to the product label for specific stability information. Typically stable until the expiration date if refrigerated.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical starting dose of survodutide?
The typical starting dose is 0.6 mg injected subcutaneously once weekly. This is then gradually escalated to minimize gastrointestinal side effects.
How long does it take to see results with survodutide?
Significant weight loss and improvements in liver fat can be observed within 12-24 weeks of treatment, with further benefits continuing over 48 weeks or longer. Individual results may vary.
What if I miss a dose of survodutide?
If you miss a dose, administer it as soon as possible within 5 days of the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.
Can I take survodutide if I have kidney problems?
Consult with your healthcare provider. Survodutide has not been extensively studied in individuals with severe kidney impairment, and dose adjustments may be necessary.

Last updated: 2026-02-21